Ketha Hemamalini, Wadams Heather, Lteif Aida, Singh Ravinder J
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States.
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, United States.
J Steroid Biochem Mol Biol. 2015 Apr;148:14-8. doi: 10.1016/j.jsbmb.2015.01.022. Epub 2015 Jan 27.
Public concern over vitamin D deficiency has led to widespread use of over the counter (OTC) vitamin D (-D3 or -D2) supplements, containing up to 10,000 IU/unit dose (400 IU=10μg). Overzealous use of such supplements can cause hypercalcemia due to vitamin D toxicity. Infants are particularly vulnerable to toxicity associated with vitamin D overdose. OTC supplements are not subject to stringent quality control regulations from FDA and high degree of variability in vitamin D content in OTC pills has been demonstrated. Other etiologies of vitamin D induced hypercalcemia include hyperparathyroidism, granulomatous malignancies like sarcoidosis and mutations in the CYP24A1 gene. The differential diagnosis of hypercalcemia should include iatrogenic and genetic etiologies. C24-hydroxylation and C3-epimerization are two important biochemical pathways via which 25-hydroxyvitamin D3 (25(OH)D3) is converted to its metabolites, 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) or its C3 epimer, 3-epi-25-OH-D3 respectively. Mutations in the CYP24A1 gene cause reduced serum 24,25(OH)2D3 to 25(OH)D3 ratio (<0.02), elevated serum 1,25-dihydroxyvitamin D (1,25(OH)2D3), hypercalcemia, hypercalciuria and nephrolithiasis. Studies in infants have shown that 3-epi-25(OH)D3 can contribute 9-61.1% of the total 25(OH)D3. Therefore, measurements of parathyroid hormone (PTH) and vitamin D metabolites 25(OH)D3, 1,25(OH)2D3, 3-epi-25(OH)D3 and 24,25(OH)2D3 are useful to investigate whether the underlying cause of vitamin D toxicity is iatrogenic versus genetic. Here we report a case of vitamin D3 associated toxicity in a 4-month-old female who was exclusively breast-fed and received an oral liquid vitamin D3 supplement at a dose significantly higher than recommended on the label. The vitamin D3 content of the supplement was threefold higher (6000 IU of D/drop) than listed on the label (2000 IU). Due to overdosing and higher vitamin D3 content, the infant received ∼50,000 IU/day for two months resulting in severe hypercalcemia, hypercalciuria and nephrocalcinosis. We also review the relevant literature on vitamin D3 toxicity in this report.
公众对维生素D缺乏的关注导致非处方(OTC)维生素D(-D3或-D2)补充剂的广泛使用,每单位剂量含高达10,000 IU(400 IU = 10μg)。过度使用此类补充剂可因维生素D中毒导致高钙血症。婴儿尤其易受维生素D过量相关毒性的影响。OTC补充剂不受美国食品药品监督管理局(FDA)严格的质量控制法规约束,并且已证明OTC药丸中维生素D含量存在高度变异性。维生素D诱导的高钙血症的其他病因包括甲状旁腺功能亢进、结节病等肉芽肿性恶性肿瘤以及CYP24A1基因突变。高钙血症的鉴别诊断应包括医源性和遗传病因。C24-羟基化和C3-差向异构化是两条重要的生化途径,通过这些途径25-羟基维生素D3(25(OH)D3)分别转化为其代谢产物24,25-二羟基维生素D3(24,25(OH)2D3)或其C3差向异构体3-表-25-OH-D3。CYP24A1基因突变导致血清24,25(OH)2D3与25(OH)D3的比值降低(<0.02)、血清1,25-二羟基维生素D(1,25(OH)2D3)升高、高钙血症、高钙尿症和肾结石。对婴儿的研究表明,3-表-25(OH)D3可占总25(OH)D3的9 - 61.1%。因此,测量甲状旁腺激素(PTH)和维生素D代谢产物25(OH)D3、1,25(OH)2D3、3-表-25(OH)D3和24,25(OH)2D3有助于调查维生素D毒性的潜在原因是医源性还是遗传性。在此,我们报告一例4个月大纯母乳喂养的女性维生素D3相关中毒病例,该婴儿接受了一种口服液体维生素D3补充剂,其剂量明显高于标签上的推荐剂量。该补充剂的维生素D3含量比标签上列出的(2000 IU)高三倍(每滴含6000 IU的D)。由于过量用药和维生素D3含量较高,该婴儿连续两个月每天摄入约50,000 IU,导致严重的高钙血症、高钙尿症和肾钙质沉着症。我们还在本报告中回顾了关于维生素D3毒性的相关文献。